Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Joint Bone Spine ; 90(3): 105555, 2023 05.
Artigo em Inglês | MEDLINE | ID: mdl-36842760

RESUMO

INTRODUCTION: Clinical and immunological features of patients with cancer-associated systemic sclerosis: an observational study. OBJECTIVE: Several studies have reported an increased incidence of cancer in patients with systemic sclerosis (SSc). The presence of RNA polymerase III antibodies (anti-RNA Pol 3) associates with an increased risk of cancer, but other risk factors need yet to be identified. We aimed to assess clinical and immunological predictive factors of cancer-associated SSc to guide clinicians when setting up selective cancer screening. METHODS: We conducted a monocentric, retrospective, observational study of SSc patients with and without associated malignancy. Clinical, laboratory and imaging data were collected, as well as SSc treatment. Subgroup analyses were performed according to the type of cancer and the time of diagnosis. RESULTS: Of 464 SSc patients, 74 (16%) had cancer, with breast (n=26) and lung cancer (n=13) being the most frequent. Diagnosis of cancer was made less than 3 years before or after SSc diagnosis for 23 patients (31%). In a multivariate analysis, anti-RNA Pol 3 and anti-SSA antibodies were significantly associated with an increased overall risk of cancer with an odds ratio (OR) of 4.12 (95% CI [1.6-10.7]; P<0.01) and 2.43 (95% CI [1.1-5.4]; P<0.05), respectively. Age at diagnosis of SSc and delay from the SSc diagnosis were also independent risk factors of cancer. Interstitial lung disease and anti-topoisomerase antibodies were associated with an increased risk of lung cancer and cancer occuring more than three years after SSc diagnosis. CONCLUSION: In addition to anti-RNA Pol 3 antibodies, anti-SSA antibodies associated with an increased risk of cancer in SSc patients. Interstitial lung disease was a risk factor specifically for lung cancer and cancers diagnosed more than 3 years after SSc diagnosis. For these patients, a systematic and regular cancer screening should be considered.


Assuntos
Doenças Pulmonares Intersticiais , Neoplasias Pulmonares , Escleroderma Sistêmico , Humanos , Estudos Retrospectivos , Escleroderma Sistêmico/complicações , Escleroderma Sistêmico/epidemiologia , Doenças Pulmonares Intersticiais/diagnóstico , Doenças Pulmonares Intersticiais/epidemiologia , Doenças Pulmonares Intersticiais/etiologia , Fatores de Risco , Autoanticorpos
2.
Rheumatology (Oxford) ; 61(2): 531-541, 2022 02 02.
Artigo em Inglês | MEDLINE | ID: mdl-34382085

RESUMO

OBJECTIVE: To compare the effect of the biological reference agents (infliximab, etanercept, adalimumab) in RA in pivotal superiority placebo-controlled trials (reference agent vs placebo) vs their effect in equivalence active comparator-controlled trials (reference agent vs biosimilar). METHODS: The PubMed, EMBASE and Cochrane databases were searched for randomized, double-blind, controlled trials up to March 2020 comparing a biological reference agent vs placebo or biosimilar. The study assessed the ACR 20/50/70 responses of the reference agent in these groups (Reference-pbo and Reference-bs, respectively). The effect of the reference agent in both groups was estimated with 95% CI, pooled using random-effects models and then compared using a meta-regression model. RESULTS: We included 31 trials. The main characteristics of the population (disease duration and activity, % seropositivity and methotrexate dose) of the population in both groups were similar. The meta-analysis found a better ACR20 response to the biological originator in the Reference-bs group with a global rate of 70% (95% CI, 66, 74) compared with 59% (95% CI, 55, 62) in the reference-pbo group (P =0.001). A significant difference was also found for ACR 50 [44% (95% CI, 39, 50) vs 35% (95% CI, 31, 39), respectively, P <0.01]. CONCLUSION: The effect of the reference biologic agent was better when compared with an active drug to a placebo. This could be linked to an increased placebo effect in active comparator-controlled studies or a nocebo effect in placebo-controlled studies. This effect can be called the lessebo effect.


Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Inibidores do Fator de Necrose Tumoral/uso terapêutico , Adalimumab/uso terapêutico , Produtos Biológicos/uso terapêutico , Etanercepte/uso terapêutico , Humanos , Infliximab/uso terapêutico , Placebos , Ensaios Clínicos Controlados Aleatórios como Assunto , Projetos de Pesquisa
5.
Managua; UNFPA; 1996. 30 p. ilus.
Monografia em Espanhol | LILACS | ID: lil-408419

RESUMO

El Ministerio de Salud , con el apoyo técnico y financerio del Fondo de Población de las Naciones Unidas, elaboró la maleta pedagógica y el presente material educativo con el fin de propiciar la capacitación de las enfermeras de Nicaragua en materia de salud reproductiva. Este es un paso fundamental en el proceso de mejoramiento de la calidad de la atención en los servicios de salud. Esta maleta sirve como recurso didáctico para el personal docente responsable de orientar el proceso educativo y hace énfasis en toda la problemática relativa a la planificación familiar por ser este un componente relativamente poco atendido en el enfoque de salud materno-infantil puesto en marcha en el MInisterio de Salud entre 1989 y 1993


Assuntos
Educação em Enfermagem , Serviços de Planejamento Familiar , Cuidados de Enfermagem , Recursos Humanos de Enfermagem , Serviços de Saúde Reprodutiva , Materiais de Ensino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...